[HTML][HTML] LncRNA-miRNA axis in tumor progression and therapy response: An emphasis on molecular interactions and therapeutic interventions

M Entezari, A Taheriazam, S Orouei, S Fallah… - Biomedicine & …, 2022 - Elsevier
Epigenetic factors are critical regulators of biological and pathological mechanisms and they
could interact with different molecular pathways. Targeting epigenetic factors has been an …

Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: from prediction to druggability

GC Eptaminitaki, D Stellas, B Bonavida… - Drug Resistance Updates, 2022 - Elsevier
The acquisition of cancer cell resistance to conventional chemotherapeutics is considered
the major driver of treatment failure and disease recurrence in most solid and hematological …

[HTML][HTML] MicroRNA as a potential therapeutic molecule in cancer

J Szczepanek, M Skorupa, A Tretyn - Cells, 2022 - mdpi.com
Small noncoding RNAs, as post-translational regulators of many target genes, are not only
markers of neoplastic disease initiation and progression, but also markers of response to …

[HTML][HTML] MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells

M Moghbeli - Journal of ovarian research, 2021 - Springer
Background Ovarian cancer (OC) is one of the leading causes of cancer related deaths
among women. Due to the asymptomatic tumor progression and lack of efficient screening …

[HTML][HTML] Distinct regulatory functions and biological roles of lncRNA splice variants

MR Khan, M Avino, RJ Wellinger, B Laurent - Molecular Therapy-Nucleic …, 2023 - cell.com
Alternative splicing (AS) of RNA molecules is a key contributor to transcriptome diversity. In
humans, 90%–95% of multi-exon genes produce alternatively spliced RNA transcripts …

ceRNA networks in gynecological cancers progression and resistance

S Wu, B Zhong, Y Yang, Y Wang… - Journal of Drug Targeting, 2023 - Taylor & Francis
Gynecological cancers are the second most common types of cancer in women. Clinical
diagnosis of these cancers is often delayed or misdiagnosed due to lack of insight into their …

[HTML][HTML] Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing

I Psilopatis, AG Sykaras, G Mandrakis, K Vrettou… - Biomedicines, 2022 - mdpi.com
Ovarian cancer (OC) is the leading cause of death from gynecological malignancies.
Despite great advances in treatment strategies, therapeutic resistance and the gap between …

[HTML][HTML] An unanticipated modulation of cyclin-dependent kinase inhibitors: the role of long non-coding RNAs

D Bencivenga, E Stampone, A Vastante, M Barahmeh… - Cells, 2022 - mdpi.com
It is now definitively established that a large part of the human genome is transcribed.
However, only a scarce percentage of the transcriptome (about 1.2%) consists of RNAs that …

Long non‑coding RNA LINC01960‑201 hinders decidualization of endometrial stromal cell in endometriosis: Relevance to endometrial receptivity

H Cai, J Lang - Molecular medicine reports, 2022 - spandidos-publications.com
Emerging data have indicated that long non‑coding RNAs (lncRNA) are associated with the
pathogenesis of endometriosis. However, few are associated with endometriosis‑associated …

[HTML][HTML] Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology

L Thorel, M Perréard, R Florent, J Divoux… - … & Molecular Medicine, 2024 - nature.com
Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has
broadened the repertoire of preclinical models and progressively revolutionized three …